Aitken Klee LLP
Since its inception in 2013, Aitken Klee LLP has consistently been recognised as one of the leading IP litigation firms in Canada. We are the go-to firm when other IP firms need external counsel. We represent clients in all areas of intellectual property, including medical devices, biotechnology, resource industries, consumer goods, food products, aerospace and pharmaceuticals.
Our team has successfully represented clients in high-stakes patent litigation in the natural resources sector involving technology from hard rock directional drilling to oils sands tailings pond remediation. Our lawyers were successful as lead counsel on the seminal case that defined the test for anticipation by prior use in Canada in the context of a patent for a method to remove hydrogen sulphide from natural gas (Baker Petrolite Corp v Canwell Enviro-Industries Ltd, 2002 FCA 158). We represent Coil Solutions Inc in a suit by Varco I/P Inc for infringement of a patented coiled tubing injector system (Varco I/P Inc v Coil Solutions Inc, T-229-18). We represent Aziwell in a patent infringement suit by Devicos AS with respect to directional drilling technology (T-429-18). We successfully represented Thermon Manufacturing Co in resisting an application to amend the named inventors of a patent on pipe heating cable used in mining operations (Drexan Energy Systems Inc v Canada (Commissioner of Patents), 2014 FC 887). We successfully defended Suncor Energy Inc in a patent infringement action in the Federal Court of Canada involving Suncor’s oil sands tailings pond remediation technology.
Aitken Klee also has an unrivalled track record successfully representing pharmaceutical manufacturers in patent litigation under both the Patent Act and the Patented Medicines (Notice of Compliance) Regulations, including at the Supreme Court of Canada. In small molecule drugs, we have taken on some of the most difficult cases, including successfully addressing numerous compound, formulation and use patents on blockbuster drugs. We have also been successful in a number of seminal cases, including defining the requirements of written description and clarifying the meaning of ‘inventive concept’, that continue to shape Canadian patent law and have twice won a prestigious patent case of the year award.
Complementing its litigation experience, our team has the deep technical background required for biopharmaceutical and biosimilar products. Nearly half of our lawyers have a life sciences master’s or doctoral degree, including those with first-hand experience in the expression and high-resolution characterisation of recombinant protein products. Our team was counsel in the first biosimilar litigation in Canada involving filgrastim.
Our lawyers have a long history of representing innovative and successful medical device companies, from large multinational corporations to start-ups. Our lawyers combine their strong technical backgrounds with their world-class litigation experience to achieve creative and successful results for our clients. Our lawyers represent LivaNova and Boston Scientific as its Canadian counsel in a multi-jurisdictional dispute over patents related to transcatheter aortic valve replacement (T-1831-16). We successfully defended WL Gore & Associates in a patent infringement case involving artificial blood vessels against Bard Peripheral Vascular. The corresponding litigation in the United States was described by the court as the most complicated case the court had presided over (T-2105-13).
Aitken Klee LLP
100 Murray Street
Ottawa ON K1N 0A1
- Marcus Klee, Managing partner